Cambridge Healthtech Institute’s 10th Annual
Next Generation Histone Deacetylase Inhibitors
New Chemistries. New Biology. New Combination Therapies.

Part of the 14th Annual Discovery on Target Conference
September 19, 2016 | Westin Boston Waterfront | Boston, MA

Histone deacetylases (HDACs) have proven to be a promising target for drug intervention and there are a number of HDAC inhibitors (HDACi) currently being tested at various pre-clinical and clinical stages. HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating neurodegenerative, immunologic, metabolic, inflammatory and cardiovascular disorders. More recently, they are being developed as combination treatments along with small molecule cancer immunotherapy agents. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that are triggered downstream. Cambridge Healthtech Institute’s annual symposium on Next Generation Histone Deacetylase Inhibitors, tracks both the scientific and clinical progress being made to better understand the cellular function of this complex drug target family. The interactive sessions and panel discussions are all geared to provide ample opportunity for active networking, brainstorming and collaborating.

Who should attend: Students, Post-docs, Lab Technicians, Managers, Scientists, Clinicians, Team Leads, Directors and Executives from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in Drug Discovery of Epigenetic Targets, Functional Screening, Compound Screening, Target ID and Validation, Biomarker Discovery, and Translational Research.

Topics will include, but are not limited to:

  • Developing HDACi in combination treatments for small molecule cancer immunotherapy
  • Exploiting new HDAC chemistries for better specificity
  • Exploring HDAC biology using chemical probes, imaging and more
  • Using structural biology to guide chemical design
  • Screening HDAC inhibitors: Use of animal models and in vitro assays
  • Evaluating the use of pan versus isoform-specific inhibitors
  • Non-oncology applications of HDACi
  • Update on novel HDACi; preclinical and clinical progress update

If you are interested in speaking, please click here.

Click here to register for a special early-bird discounted rate.

The deadline for submission is March 4, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483